Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as GBX 4.51 and last traded at GBX 4.92, with a volume of 558574 shares traded. The stock had previously closed at GBX 5.
Allergy Therapeutics Price Performance
The firm has a market cap of £311.88 million, a P/E ratio of -5.08, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The firm’s 50 day moving average is GBX 5.87 and its 200 day moving average is GBX 8.46.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
- Copper Is the AI Trade No One Priced In—3 Miners With the Most to Gain
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
